Given the growing interest in targeting transcriptional dependencies in MYCN-amplified cancers, therapeutic inhibition of NIPBL will offer a promising strategy to disrupt MYCN-driven oncogenic networks and restore differentiation potential in high-risk neuroblastoma. The gene discussed is MYCN; the disease is cancer.